AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
ApexOnco Front Page
Recent articles
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
In first-line NSCLC the drug beats chemo, and not Keytruda.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
And the company might one day follow Galapagos into decentralised manufacturing.
